Skip to content

Study · Case report or series · n = 1 · 2026

2 results

Hemodynamic Compromise Due to Semaglutide-Associated Abdominal Distension.

Amdahl MB, Bharadiya V, Obritsch B, Obadi O, Wong MY, Rode MM, Colletti J, Cortes Puentes GA, Chen J, Dahiya G

JACC. Case reports30 Sept 2026

PMID42820899 (opens in a new tab)DOI10.1016/j.jaccas.2026.110452 (opens in a new tab)PepBankPUB-42820899
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 35-year-old man with obesity, restarting high-dose semaglutide was followed by massive gastric distension with inferior vena cava compression.

    In plain wordsA young man with obesity developed a hugely swollen stomach after restarting a high dose of semaglutide. This is one case only.

    Peptide
    Semaglutide
    Outcome
    Not applicableMassive gastric distension with IVC compression
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    maximum doseAs given in this study (human).

    Source sentences

    Summary
    Imaging showed massive gastric distension with significant inferior vena cava compression.
    2 context sentences
    Summary · context
    This case represents a heretofore unseen side effect of glucagon-like peptide-1 receptor agonist administration, with initiation of maximum-dose semaglutide leading to dramatic gastric distension causing inferior vena cava compression and low-output shock.
    Summary · context
    A 35-year-old male patient with obesity and otherwise minimal medical history presented to the emergency department after a syncopal episode that occurred several days after restarting high-dose GLP-1 agonist therapy.
  2. 02HumanCase report or seriesSafety outcome

    In the same patient, gastric distension led to low-output shock that needed very high-dose vasoactive medications and resolved after gastric decompression.

    In plain wordsIn this one patient, the swollen stomach led to dangerously low blood flow. It improved after the stomach was emptied.

    Peptide
    Semaglutide
    Outcome
    Not applicableLow-output shock
    Study

    n = 1

    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    maximum doseAs given in this study (human).

    Source sentences

    Summary
    He developed low-output shock requiring very high-dose vasoactive medications, which resolved after gastric decompression via emesis, nasogastric tube placement, and intravenous fluid resuscitation.
    2 context sentences
    Summary · context
    This case represents a heretofore unseen side effect of glucagon-like peptide-1 receptor agonist administration, with initiation of maximum-dose semaglutide leading to dramatic gastric distension causing inferior vena cava compression and low-output shock.
    Summary · context
    A 35-year-old male patient with obesity and otherwise minimal medical history presented to the emergency department after a syncopal episode that occurred several days after restarting high-dose GLP-1 agonist therapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.